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Abstract: The Pseudomonas quinolone system (PQS) is one of the three major interconnected quorum
sensing signaling systems in Pseudomonas aeruginosa. The virulence factors PQS and HHQ activate the
transcription regulator PqsR (MvfR), which controls several activities in bacteria, including biofilm
formation and upregulation of PQS biosynthesis. The enzyme anthraniloyl-CoA synthetase (PqsA)
catalyzes the first and critical step in the biosynthesis of quinolones; therefore, it is an attractive target
for the development of anti-virulence therapeutics against Pseudomonas resistance. Herein, we report
the design and synthesis of novel triazole nucleoside-based anthraniloyl- adenosine monophosphate
(AMP) mimics. These analogues had a major impact on the morphology of bacterial biofilms and
caused significant reduction in bacterial aggregation and population density. However, the compounds
showed only limited inhibition of PQS and did not exhibit any effect on pyocyanin production.
Keywords: Pseudomonas quinolone system; quorum sensing; Pseudomonas aeruginosa; virulence
factors; biofilm; anthraniloyl-AMP mimics; pyocyanin production
1. Introduction
Antimicrobial resistance (AMR) is a growing threat to global public health. The Organization for
Economic Co-operation and Development (OECD) has predicted that resistant microbial infections
would be the leading cause of mortality in the next 30 years, and that around 2.4 million people will
die in Europe, North America, and Australia alone. The problem of AMR is even more acute in low
and middle-income countries, such as India, Brazil, and Indonesia, where 40–60% of infections are
already caused by multidrug-resistant microbes [1,2].
The rapid rise of AMR has created fears that the medical system will soon become overwhelmed
with “superbugs”, which are pathogenic bacterial strains that fail to respond to any antibiotic
treatment [3]. Recently, the World Health Organization (WHO) has submitted a list of pathogenic
bacterial strains that require the most urgent attention for therapeutic intervention [4]. One of the
bacteria in the critical priority class is Pseudomonas aeruginosa. Multidrug-resistant P. aeruginosa strains
are a leading cause of acute and chronic infections, particularly in immunocompromised patients such
as those suffering from other illnesses including cancer, burns and cystic fibrosis [5]. Furthermore,
P. aeruginosa can switch from a planktonic (free-living) form to a sessile (community) form by the
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formation of a biofilm, which greatly contributes to drug resistance. Bacteria in biofilms are about
1000-fold more resistant to antibiotics than planktonic bacteria [6,7].
Only a few classes of antibacterial agents like Oxazolidinones and Lipopeptides with new modes
of action have been approved for clinical use since the 1970s. Most of the antibacterial drugs introduced
over the last several decades have been obtained by structural modification of existing drugs like
Amoxicillin and Azithromycin. As these analogues possess similar mechanisms of action as their
predecessors, they are highly susceptible to AMR [8,9]. In this context, there is an urgent need for the
development of drugs that inhibit the colonization and virulence of bacteria without exerting selective
pressure on bacteria to develop resistance.
Quorum sensing (QS) is an intercellular communication system in bacteria. It is a chemical process
which involves the synthesis and release of diffusible quorum sensing signaling molecules (QSSMs),
also known as autoinducers (AIs). When the bacterial population grows, the concentration of these
AIs in the surrounding environment increases. After a certain threshold is passed, the AIs will activate
multiple genes that regulate the collective behavior of bacteria, including activities related to virulence,
motility, swarming, biofilm formation and antibiotic resistance [10–12].
Inhibition of QS-mediated bacterial communication by small molecules is now considered to
be contemporary approach to overcome AMR. The main idea is to inhibit bacterial virulence factors
and attenuate biofilm formation without affecting bacterial growth. QS inhibitors (QSIs) do not kill
bacteria, and therefore, exert minimum selective pressure on bacteria to develop AMR. Furthermore,
QSIs can be used as a combination therapy with conventional antibiotics to give synergistic effects,
particularly when the infection is caused by resistant bacteria [13–15].
P. aeruginosa employs las, rhl and pqs as its major QS systems. Although these QS systems use
different kinds of AIs, they are interconnected and modulate the activities of each other. For example,
las upregulates the rhl and pqs systems, while rhl downregulates pqs [16,17]. The las and rhl systems use
the structurally related chemical class of N-acyl homoserine lactones (AHLs) as AIs. These molecules
bind and activate their corresponding LuxR-type cognate receptor proteins LasR and RhlR, which leads
to the upregulation of the expression of genes associated with virulence and biofilm formation [18].
In contrast, the Pseudomonas quinolone signaling (pqs) system is based on the
chemical class of 2-alkyl-4(1H)-quinolones (AQs) as signal molecules. In P. aeruginosa,
2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) and its immediate biosynthetic precursor,
2-heptyl-4-hydroxyquinoline (HHQ), are the most common QSSMs. However, there are more than
50 other AQs, such as 2-alkyl 4-hydroxy quinoline N-oxide and other C-9 congeners of PQS and
HHQ. All these molecules activate the protein receptor PqsR (also known as MvfR), leading to the
upregulation of the pqsABCDE operon, which further promotes the biosynthesis of PQS through
positive feedback as well as increasing the expression of genes associated with bacterial defense
mechanisms, including biofilm formation and production of virulence factors [17]. Furthermore,
PQS-mediated bacterial aggregation and biofilm formation in P. aeruginosa are triggered through
different mechanisms, including chemical signaling among bacterial cell population, production of
iron-chelating molecules (siderophore), virulence factor pyocyanin biosynthesis and regulation of
extracellular DNA (eDNA) release through prophage induction, vesicles production and pyocyanin
mediated eDNA release [19–22].
Biosynthesis of AQs involves several different enzymatic reactions. The initial substrate
is anthranilic acid, which is converted to anthranilate–CoA by the enzyme PqsA (Figure 1).
Anthranilate–CoA is transformed through multiple steps into HHQ by enzymes PqsD, PqsE and
PqsBC. Finally, the enzyme PqsH catalyzes the hydroxylation of HHQ to form PQS. Hence, the two
main ways to block the PQS QS system are to inhibit PQS biosynthesis by targeting its biosynthetic
enzymes, and prevention of signal transduction by PqsR receptor antagonists [23–25].





Figure 1. Schematic diagram of PQS biosynthesis, leading to activation of PqsR (MvfR) and 
expression of the pqsABCDE operon. 
PqsA is an acyl-CoA synthetase enzyme belonging to the ANL superfamily of structurally 
related adenylating enzymes. PqsA catalyzes the first and key step in the biosynthesis of PQS, which 
involves transformation of anthranilic acid to anthranilate–CoA. Mechanistically, PqsA first 
catalyzes the ATP-dependent adenylation of anthranilic acid to form an anthranilate-AMP 
intermediate, which subsequently reacts with CoA-SH in a thioesterification reaction to yield 
anthranilate–CoA (Figure 2). PqsA possesses some attractive features that validates it as a promising 
target for antimicrobial drug discovery. For example, PqsA-deficient mutant strains show reduced 
HHQ and PQS biosynthesis and poor biofilm formation in cell culture, as well as highly attenuated 
virulence in animal infection models. PqsA-deficient mutants also exhibit increased sensitivity 
towards antimicrobial therapy in vivo. PqsA inhibitors decrease PQS production and reduce 
mortality in a mice infection model [26]. Importantly, PqsA is exclusively present in bacterial cells, 
therefore, selective PqsA inhibitors are unlikely to affect host cell viability.     
 
Figure 2. PqsA catalyzes the conversion of anthranilic acid to anthraniloyl-CoA—the first step of 
PQS biosynthesis. 
Despite its essential role in the biosynthesis of PQS, only few attempts to inhibit the PqsA 
enzyme have been reported so far (Figure 3). Halogenated anthranilic acids have been reported as 
competitive inhibitors of PqsA, however, they showed only weak inhibition, as millimolar 
concentrations are required to show any effect [23]. Recently, Ji et al. reported sulfonyl 
adenosine-based small molecule inhibitors mimicking the anthraniloyl-AMP intermediate for the 
Figure 1. Schematic diagram of PQS biosynthesis, leading to activation of PqsR (MvfR) and expression
of the pqsABCDE operon.
PqsA is an acyl-CoA synthetase enzyme belonging to the ANL superfamily of structurally
related adenylating enzymes. PqsA catalyzes the first and key step in the biosynthesis of PQS,
which involves transformation of anthranilic acid to anthranilate–CoA. Mechanistically, PqsA first
catalyzes the ATP-dependent adenylation of anthranilic acid to form an anthranilate-AMP intermediate,
which subsequently reacts with CoA-SH in a thioesterification reaction to yield anthranilate–CoA
(Figure 2). PqsA possesses some attractive features that validates it as a promising target for antimicrobial
drug discovery. For example, PqsA-deficient mutant strains show reduced HHQ and PQS biosynthesis
and poor biofilm formation in cell culture, as well as highly attenuated virulence in animal infection
models. PqsA-deficient mutants also exhibit increased sensitivity towards antimicrobial therapy
in vivo. PqsA inhibitors decrease PQS production and reduce mortality in a mice infection model [26].
Importantly, PqsA is exclusively present in bacterial cells, therefore, selective PqsA inhibitors are
unlikely to affect host cell viability.
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Figure 2. PqsA catalyzes the conversion of anthranilic acid to anthraniloyl-CoA—the first step of
PQS biosynthesis.
espit its essential role in the biosynthesi of PQS, only few attempts to inhibit the PqsA enzyme
have been r ported so fa (Figure 3). Halogenat d anthranilic acids have been reported as comp titive
inhibitors of PqsA, owever, they howed only weak in ibition, as millimolar conce trations are
required to show any effect [23]. Recently, Ji et l. reported sulfonyl adenosine-based small molecule
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inhibitors mimicking the anthraniloyl-AMP intermediate for the competitive inhibition of PqsA.
While these inhibitors showed high binding affinity (Ki < 0.2 µM) for the PqsA enzyme, they did
not exhibit satisfactory antibacterial potency in vitro (IC50 > 300 µM). Compound accumulation
studies showed poor bacterial cell permeability, which possibly limited their cellular activity [26].
Recently, the crystal structures of PqsA complexed with the ligand anthraniloyl-AMP with the inhibitor
6-fluoroanthraniloyl-AMP (6-FABA-AMP) were reported by Witzgall et al. [27]. The structures revealed
that the N-terminal domain of PqsA contains the active site that recognizes and binds the natural
ligand anthraniloyl-AMP as well as the competitor inhibitor, 6-FABA-AMP.
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P. aeruginosa, which limits their further development as novel antimicrobi l agents.
cle ti e analogues can be generated by modifications of the p os ate backbone, ribose sugar
or b se [28]. To develop nonpolar nucleotide analogues of anthraniloyl-AMP, we first used the neutral
triazole linker as an isostere for the charged phosphodiester linkage. One adva tage of using triazole
is that it is metabolically m re stable than the phosphodiester linkag , because of its resistance to
d gradation by nucle se. The second modification was to repl ce the denin base of anthraniloyl-AMP
wit pyrimidine bases, such as thymidine, 2′-deoxyuridine and 2′-deoxycytidine [29]. Finally, the ribos
sugar of the natural ligand was replaced with 2′- eoxyribose (Figure 4).
The synthetic route for the synthesis of the novel triazole-linked anthranilamide deoxynucleoside
compounds began with the ring-opening of 5-substituted isatoic anhydrides (1a–e) using
propargylamine (2) under mild reaction conditions. Different terminal alkyne-containing
anthranilamide intermediate compounds (3a–e) were synthesized in excellent yields (Scheme 1).
Next, we synthesized nucleoside azides following a reported protocol [30]. Selective tosylation
of the primary hydroxy group of thymidine nucleoside (4) using pyridine and tosyl chloride at 0 ◦C
generated tosylate (5), which was further converted to the corresponding azide (6) by a nucleophilic
substitution reaction with sodium azide in DMF at 70 ◦C (Scheme 2).
The final step involved an azide–alkyne cycloaddition (click chemistry) reaction between alkynes
(3a–e) and thymidine azide (6). The reaction was performed in the presence of CuSO4 catalyst
and sodium ascorbate as reducing agents in t-BuOH:H2O (1:1) medium [31]. The desired triazolo
nucleosides (7a–e) were synthesized between 59–74% yields (Scheme 3).
Furthermore, 2′-deoxyuridine (8) was converted to the corresponding triazole nucleoside
analogues (9a–c) and (9e) by using the same three-step reaction sequence in moderate to good
isolated yields (Scheme 4).
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For PQS inhibition assay, all the new triazole nucleotide analogues were screened for their ability
to inhibit the pqs QS system using the PAO1 (a P. aeruginosa reporter strain) pqsA:gfp reporter assay.
This assay measures the PqsR (MvfR) regulated expression of the pqsABCDE operon. It is expected
that the PqsA inhibitors will block the biosynthesis of PQS and HHQ, which leads to lower activation
of the PqsR (MvfR) receptor and ultimately, reduction in the expression of the pqsABCDE reporter.
The expression of the reporter in the untreated control reached its maximum level after 6–8 h which
then fell to basal expression levels at later time points. A known inhibitor of PQS was employed as a
positive control which prevented this expression [33]. Preliminary assays revealed that concentrations
of DMSO above 1.25% inhibited GFP expression of the reporter, even without the presence of any of the
test compounds, although growth was unaffected. Therefore, the final DMSO concentration was kept
at 1.25%. Based on the concentration of our compound stock solutions, this corresponded to 125 µg/mL
as the highest concentration tested for each compound. Then, two-fold lower serial dilutions of the
compound were tested whilst keeping the DMSO concentration constant. All compounds except one
showed no or very slight inhibition of the pqsA reporter at all concentrations tested. Only 13e at
125 µg/mL (400 µM approx.) showed approximately 30% inhibition of the reporter when compared
to the negative control (Figure 6, Table 1). The LogP value of the compound plays a critical role in
bacterial cell penetration and the cLogP value of compound 13e (−0.55) is highest among cytidine
triazoles, which indicates that the compound 13e could be more permeable to bacterial cells compared
to all other derivatives.
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Table 1. PQS inhibition by synthesized compounds using PAO1 pqsA:gfp reporter-based assay.
Compound Name Biological Activity(Inhibition of pqsA:gfp) Inhibition (%)
1 7a No inhibition -
2 7b No inhibition -
3 7c No inhibition -
4 7d No inhibition -
5 7e No inhibition -
6 9a No inhibition -
7 9b No inhibition -
8 9c No inhibition -
9 9e No inhibition -
10 13a No inhibition -
11 13b No inhibition -
12 13c No inhibition -
13 13d No inhibition -
14 13e Inhibition 30
For inhibition of biofilm formation, some of the representative compounds (7a, 7e, 9a, 9e, 13d
and 13e) were tested for their potential ability to inhibit P. aeruginosa biofilm formation. PAO1 planktonic
cultures were incubated with 400 µM of compounds and added to microtiter wells to initiate bacterial
adhesion and biofilm growth. After 24 h, biofilms were visualized using phase contrast microscopy [34].
The compounds exerted a major impact on the morphology of bacterial biofilms. A drastic reduction in
bacterial aggregation and population density was observed in the presence of compounds 13e and 13d
as compared to both untreated and DMSO controls (Figure 7). Since the PQS system mediates bacterial
aggregation and biofilm formation in P. aeruginosa, this result could indicate that the compounds
interfere with PQS biosynthesis to reduce bacterial aggregation. However, given the weak PQS
inhibitory activity of the compounds in the in vitro reporter assay, we do not exclude the possibility
that the compounds might be acting through alternative pathways to inhibit biofilm formation.
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For the pyocyanin inhibition assay, to investigate the activity of these compounds against bacterial
virulence factors, some of the derivatives (7a, 7e, 9a, 9e, 13d and 13e) were evaluated for their ability to
inhibit the production of pyocyanin from P. aeruginosa PA01 at 400 µM concentration. However, out of
six compounds tested, none of them showed any significant decrease in the production of pyocyanin.
The findings in this study match with previously published data showing compounds were effective in
inhibiting PQS biosynthesis without any impact on pyocyanin production [26]. This is an indication of
the complex relationship between the PQS biosynthesis and pyocyanin production.
Regarding effect on growth, none of the compounds had any effect on growth at concentrations
up to 256 µg/mL except for 7a. For 7a, even the 32 µg/mL concentration was enough to affect growth
and increase the lag phase. For all compounds, growth was inhibited at 512 µg/mL, although this
could be due to the amount of DMSO present, since 5.12% DMSO alone affected growth (for details,
see Supporting Information).
4. Materials and Methods
4.1. Synthesis
All the reagents and solvents were purchased from commercial sources (Combi-Blocks,
Oakwood Chemicals, Sigma-Aldrich, Sydney, Australia) and used without further purification.
Reactions were performed using oven-dried glassware under an atmosphere of nitrogen (if required).
Room temperature refers to the ambient temperature (25 ◦C). Yields refer to compounds isolated after
flash column chromatography unless otherwise stated. Progress of the reactions were monitored by
thin layer chromatography (TLC) precoated with Merck silica gel 60 F254 plates and visualization
using UV light (254 nm). Flash column chromatography was carried out using Grace Davison
LC60A 40–63 µm silica gel as the stationary phase and solvent gradient (methanol in ethyl acetate)
used as the mobile phase. High-resolution mass spectrometry (HRMS) was performed at Bioanalytical
Mass Spectrometry Facility, UNSW by electrospray (ESI) ionization using a Thermo LTQ Orbitrap XL
instrument (Thermo Scientific, Waltham, MA, USA). 1H- and 13C-NMR was recorded in deuterated
solvent (DMSO-d6) using Bruker Avance 300, 400 or 600 MHz instruments (Bruker Pty Ltd., Preston,
NSW, Australia) at 24 ◦C. Chemical shifts (δ) are reported as relative to the corresponding solvent peak,
with tetramethylsilane as the internal standard and quoted in parts per million (ppm). Multiplicities
in the NMR spectra are described as: s—singlet; d—doublet; t—triplet; q—quartet; m—multiplet;
b—broad; coupling constants (J) are reported in hertz (Hz).
General procedure (A) for the ring opening of isatoic anhydrides (Synthesis of compounds 3a–3e):
To a solution of isatoic anhydride (3.0 mmol) in THF (20 mL), propargyl amine (4.5 mmol) was added
at 0 ◦C, and reaction stirred at rt for 2 h. After completion of the reaction as indicated by TLC,
the solvent was evaporated and residue was dissolved in minimum DCM, then, excess hexane was
added, and precipitate was collected and dried, which gives desired ring opened terminal alkyne
products from 89–99% yields.
2-Amino-5-methoxy-N-(prop-2-yn-1-yl)benzamide (3b): Following the general procedure A, the title
product was obtained as brown solid (607mg, 99%); 1H-NMR (400 MHz, DMSO-d6): δ 8.65 (t, J = 5.6 Hz,
1H, NH), 7.06 (d, J = 2.9 Hz, 1H, Ar-H), 6.85 (dd, J = 8.9, 2.9 Hz, 1H, Ar-H), 6.66 (d, J = 8.9 Hz, 1H,
Ar-H), 6.03 (s, 2H, NH2), 4.00 (dd, J = 5.6, 2.5 Hz, 2H, CH2), 3.68 (s, 3H, CH3), 3.08 (t, J = 2.5 Hz, 1H,
CH); 13C-NMR (101 MHz, DMSO-d6): δ 168.32, 149.31, 144.17, 120.20, 117.92, 113.80, 111.61, 81.62,
72.60, 55.58, 28.12; HRMS (ESI) m/z calcd. for C11H12N2O2 [M + H]+ 205.0972, found 205.0971.
2-Amino-5-fluoro-N-(prop-2-yn-1-yl)benzamide (3c): Following the general procedure A, the title
product was obtained as off-white solid (515 mg, 89%); 1H-NMR (400 MHz, DMSO-d6): δ 8.70 (t, J = 5.4,
1H, NH), 7.34 (dd, J = 10.3, 3.0 Hz, 1H, Ar-H), 7.06 (td, J = 9.0, 8.1, 3.0 Hz, 1H, Ar-H), 6.72 (dd, J = 9.1,
5.0 Hz, 1H, Ar-H), 6.35 (s, 2H, NH2), 3.99 (dd, J = 5.5, 2.5 Hz, 2H, CH2), 3.09 (t, J = 2.5, 1H, CH);
13C-NMR (101 MHz, DMSO–d6): δ 167.60, 167.57, 153.75, 151.46, 146.66, 119.67, 119.44, 117.78, 117.71,
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113.58, 113.36, 113.30, 81.37, 72.71, 28.20; HRMS (ESI) m/z calcd. For C10H9FN2O [M + H]+ 193.0772,
found 193.0771.
2-Amino-5-chloro-N-(prop-2-yn-1-yl)benzamide (3d): Following the general procedure A, the title
product was obtained as white solid (591 mg, 94%); 1H-NMR (400 MHz, DMSO-d6): δ 8.77 (t, J = 5.3,
1H, NH), 7.55 (d, J = 2.5 Hz, 1H, Ar-H), 7.17 (dd, J = 8.8, 2.5 Hz, 1H, Ar-H), 6.73 (d, J = 8.8 Hz,
1H, Ar-H), 6.59 (s, 2H, NH2), 3.98 (dd, J = 5.5, 2.5 Hz, 2H, CH2), 3.09 (t, J = 2.5 1H, CH); 13C-NMR
(101 MHz, DMSO-d6): δ 167.41, 148.78, 131.76, 127.39, 118.17, 117.75, 114.46, 81.32, 72.72, 28.21;
HRMS (ESI) m/z calcd. for C9H10ClN2O [M + H]+ 209.0476, found 209.0476.
General procedure (B) for the azide–alkyne cycloaddition reaction: To a mixture of nucleoside
azide (0.2 mmol) and corresponding alkyne (10a–e) (0.2 mmol) in (1:1) tert-butanol: water (4 mL),
sodium ascorbate (0.04 mmol) and CuSO4.5H2O (0.02 mmol) were added. The reaction mixture was
stirred at rt for 16 h. After completion of the reaction as indicated by TLC, solvent was evaporated in
vacuo. The crude was purified by silica gel column chromatography (silica gel was pre-neutralized with
1% triethylamine in ethyl acetate) using 0–20% methanol in ethyl acetate gradient system. The polarity
was gradually increased after every 100 mL of eluent. Desired compounds were eluted with 15–20%
methanol in ethyl acetate system as off-white to light brown solid between 52–74% yields.
2-Amino-N-((1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (7a): Following the general
procedure B, the title product was obtained as off-white solid (54 mg, 61%); 1H-NMR (400 MHz,
DMSO-d6): δ 11.24 (bs, 1H, NH), 8.72 (t, J = 5.7 Hz, 1H, NH), 7.93 (s, 1H, Ar-H), 7.49 (dd, J = 8.0,
1.5 Hz, 1H, Ar-H), 7.37 (d, J = 1.4 Hz, 2H, NH2 ), 7.12 (td, J = 8.5, 7.1, 1.5 Hz, 1H, Ar-H), 6.68 (dd, J = 8.3,
1.2 Hz, 1H, Ar-H), 6.48 (td, J = 8.1, 7.1, 1.2 Hz, 1H, Ar-H), 6.42 (s, 2H, NH2), 6.17 (t, J = 7.7, 6.3 Hz,
1H, CH), 5.48 (d, J = 4.3 Hz, 1H, OH), 4.67–4.51 (m, 2H, CH2), 4.44 (d, J = 5.7 Hz, 2H, CH2), 4.30–4.23
(m, 1H, CH), 4.09–4.05 (m, 1H, CH), 2.20–2.04 (m, 2H, CH2), 1.78 (d, J = 1.2 Hz, 3H, CH3); 13C-NMR
(101 MHz, DMSO-d6): δ 168.80, 163.64, 150.41, 149.77, 145.45, 136.01, 131.79, 128.11, 123.59,
116.35, 114.50, 114.15, 109.88, 84.07, 84.02, 70.79, 51.13, 37.86, 34.46, 12.04; HRMS (ESI) m/z calcd.
for C20H23N7O5 [M + H]+ 442.1833, found 442.1832.
2-Amino-N-((1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methoxybenzamide (7b): Following the
general procedure B, the title product was obtained as light brown solid (56 mg, 59%) 1H-NMR (300 MHz,
DMSO-d6): δ 11.31 (bs, 1H, NH), 8.79 (t, J = 5.7 Hz, 1H, NH), 7.95 (s, 1H, Ar-H), 7.38 (d, J = 1.5 Hz, 1H,
Ar-H), 7.10 (d, J = 2.9 Hz, 1H, Ar-H), 6.85 (dd, J = 8.8, 2.9 Hz, 1H, Ar-H), 6.67 (d, J = 8.9 Hz, 1H, Ar-H),
6.17 (t, J = 7.0 Hz, 3H, CH, NH2), 5.49 (d, J = 4.3 Hz, 1H, OH), 4.65 (dd, J = 15.7, 6.0 Hz, 2H, CH2),
4.46 (d, J = 5.6 Hz, 2H, CH2), 4.31–4.22 (m, 1H, CH), 4.13–4.05 (m, 1H, CH), 3.68 (s, 3H, OCH3),
2.23–2.04 (m, 2H, CH2), 1.79 (s, 3H, CH3); 13C-NMR (76 MHz, DMSO-d6): δ 168.47, 163.63, 150.40,
149.43, 145.35, 136.01, 123.64, 119.82, 117.92, 114.58, 111.85, 109.87, 84.06, 84.02, 70.79, 55.57, 51.14, 37.87,
34.47, 12.02; HRMS (ESI) m/z calcd. for C20H25N7O6 [M + Na]+ 494.1759, found 494.1755.
2-Amino-5-fluoro-N-((1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (7c): Following the general
procedure B, the title product was obtained as off-white solid (60 mg, 65%) 1H-NMR (400 MHz,
DMSO-d6): δ 11.29 (bs, 1H, NH), 8.80 (t, J = 5.6 Hz, 1H, NH), 7.96 (s, 1H, Ar-H), 7.40–7.30 (m, 2H,
Ar-H), 7.04 (td, J = 8.5, 2.9 Hz, 1H, Ar-H), 6.70 (dd, J = 9.0, 5.0 Hz, 1H, Ar-H), 6.31 (s, 2H, NH2),
6.17 (t, J = 7.0 Hz, 1H, CH), 5.48 (d, J = 4.2 Hz, 1H, OH), 4.72–4.55 (m, 2H, CH2), 4.45 (d, J = 5.6 Hz,
2H, CH2), 4.30–4.22 (m, 1H, CH), 4.11–4.04 (m, 1H, CH), 2.19–1.99 (m, 2H, CH2), 1.78 (s, 3H, CH3);
13C-NMR (101 MHz, DMSO-d6): δ 166.72, 163.64, 150.41, 146.20, 136.00, 123.85, 119.58, 119.12, 117.56,
113.66, 113.06, 109.88, 84.04, 70.80, 51.16, 37.88, 34.52, 12.02; HRMS (ESI) m/z calcd. for C20H22FN7O5
[M + Na]+ 482.1559, found 482.1556.
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2-Amino-5-chloro-N-((1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (7d): Following the general
procedure B, the title product was obtained as off-white solid (70 mg, 74%) 1H-NMR (400 MHz,
DMSO-d6): δ 11.30 (bs, 1H, NH), 8.87 (t, J = 5.7 Hz, 1H, NH), 7.97 (s, 1H, Ar-H), 7.57 (d, J = 2.4 Hz,
1H, Ar-H), 7.36 (s, 1H, Ar-H), 7.16 (dd, J = 8.8, 2.4 Hz, 1H, Ar-H), 6.71 (d, J = 8.8 Hz, 1H, Ar-H),
6.57 (s, 2H, NH2), 6.17 (t, J = 7.0 Hz, 1H, CH), 5.50 (d, J = 4.3 Hz, 1H, OH), 4.74–4.53 (m, 2H, CH2),
4.45 (d, J = 5.5 Hz, 2H, CH2), 4.30–4.25 (m, 1H, CH), 4.12–4.04 (m, 1H, CH), 2.22–2.02 (m, 2H, CH2),
1.78 (s, 3H, CH3); 13C-NMR (101 MHz, DMSO-d6): δ 167.61, 163.65, 150.42, 148.68, 136.01, 131.56,
127.43, 123.66, 118.06, 117.73, 114.96, 109.90, 84.05, 70.81, 51.17, 37.90, 34.52, 31.31, 12.04; HRMS (ESI)
m/z calcd. for C20H22ClN7O5 [M + H]+ 476.1444, found 476.1443.
2-Amino-5-bromo-N-((1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (7e): Following the general
procedure B, the title product was obtained as light orange solid (68 mg, 65%) 1H-NMR (400 MHz,
DMSO-d6): δ 11.29 (bs, 1H, NH), 8.87 (t, J = 5.5 Hz, 1H, NH), 7.96 (s, 1H, Ar-H), 7.67 (s, 1H, Ar-H),
7.36 (s, 1H, Ar-H), 7.26 (d, J = 8.8 Hz, 1H, Ar-H), 6.67 (d, J = 8.8 Hz, 1H, Ar-H), 6.58 (s, 2H, NH2),
6.17 (t, J = 7.0 Hz, 1H, CH), 5.48 (d, J = 4.2 Hz, 1H, OH), 4.87–4.52 (m, 2H, CH2), 4.44 (d, J = 5.5 Hz,
2H, CH2), 4.32–4.22 (m, 1H, CH), 4.15–4.04 (m, 1H, CH), 2.32–2.01 (m, 2H, CH2), 1.78 (s, 3H, CH3);
13C-NMR (101 MHz, DMSO-d6): δ 167.52, 163.65, 150.42, 149.00, 136.01, 134.25, 130.24, 128.36, 126.47,
123.73, 118.47, 115.58, 109.89, 104.90, 84.04, 70.80, 51.16, 37.90, 34.52, 12.05; HRMS (ESI) m/z calcd.
for C20H22BrN7O5 [M + H]+ 520.0938, found 520.0939.
2-Amino-N-((1-(((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (9a): Following the general procedure B, the title
product was obtained as off-white solid (60 mg, 70%); 1H-NMR (400 MHz, DMSO-d6):
δ 11.32 (bs, J = 2.2 Hz, 1H, NH), 8.72 (t, J = 5.7 Hz, 1H, NH), 7.92 (s, 1H, Ar-H), 7.56 (d, J = 8.1 Hz, 1H,
Ar-H), 7.49 (dd, J = 8.0, 1.5 Hz, 1H, Ar-H), 7.13 (td, J = 8.4, 7.0, 1.5 Hz, 1H, Ar-H), 6.69 (dd, J = 8.3, 1.2 Hz,
1H, Ar-H), 6.56–6.44 (m, 1H, Ar-H), 6.41 (s, 2H, NH2), 6.15 (t, J = 6.9 Hz, 1H, CH), 5.62 (dd, J = 8.1,
2.2 Hz, 1H, Ar-H), 5.51 (s, 1H, OH), 4.67 (dd, J = 14.2, 4.5 Hz, 1H, CH2), 4.57 (dd, J = 14.3, 7.7 Hz, 1H,
CH2), 4.45 (d, J = 5.7 Hz, 2H, CH2), 4.25–4.22 (m, 1H, CH), 4.10–4.06 (m, 1H, CH), 2.22–2.04 (m, 2H,
CH2);13C-NMR (101 MHz, DMSO-d6): δ 168.85, 163.02, 150.41, 149.74, 145.46, 140.72, 131.82, 128.15,
123.59, 116.40, 114.59, 114.26, 102.11, 84.42, 84.28, 70.78, 51.20, 38.08, 34.49; HRMS (ESI) m/z calcd.
for C19H21N7O5 [M + H]+ 428.1677, found 428.1673.
2-Amino-N-((1-(((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methoxybenzamide (9b): Following the general procedure B,
the title product was obtained as off-white solid (55 mg, 60%) 1H-NMR (400 MHz, DMSO-d6):
δ 11.34 (bs, J = 2.2 Hz, 1H, NH), 8.79 (t, J = 5.7 Hz, 1H, NH), 7.94 (s, 1H, Ar-H), 7.57 (d, J = 8.1 Hz, 1H,
Ar-H), 7.08 (d, J = 2.9 Hz, 1H, Ar-H), 6.83 (dd, J = 8.9, 2.8 Hz, 1H, Ar-H), 6.65 (d, J = 8.9 Hz, 1H, Ar-H),
6.15 (t, J = 6.9 Hz, 1H, CH), 6.03 (s, 2H, NH2), 5.62 (dd, J = 8.1, 2.0 Hz, 1H, Ar-H), 5.51 (d, J = 4.3 Hz,
1H, OH), 4.72–4.64 (m, 1H, CH2), 4.58 (dd, J = 14.2, 7.7 Hz, 1H, CH2), 4.45 (d, J = 5.7 Hz, 2H, CH2),
4.25–4.23 (m, 1H, CH), 4.10–4.05 (m, 1H, CH), 3.67 (s, 3H, OCH3) 2.21–2.10 (m, 2H, CH2); 13C-NMR
(101 MHz, DMSO-d6): δ 168.56, 163.01, 150.41, 149.33, 145.39, 144.00, 140.74, 123.64, 119.90,
117.84, 114.33, 111.82, 102.10, 84.40, 84.29, 70.78, 55.58, 51.22, 38.08, 34.49; HRMS (ESI) m/z calcd.
for C20H24N7O6 [M + H]+ 458.1783, found 458.1781.
2-Amino-N-((1-(((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-fluorobenzamide (9c): Following the general procedure B,
the title product was obtained as off-white solid (64 mg, 72%); 1H-NMR (400 MHz, DMSO-d6):
δ 11.32 (bs, 1H, NH), 8.80 (t, J = 5.7, 1H, NH), 7.95 (s, 1H, Ar-H), 7.55 (d, J = 8.1 Hz, 1H, Ar-H),
7.36 (dd, J = 10.3, 3.1 Hz, 1H, Ar-H), 7.03 (dt, J = 8.5, 4.3 Hz, 1H, Ar-H), 6.70 (dd, J = 9.1, 5.0 Hz, 1H,
Ar-H), 6.31 (s, 2H, NH2), 6.14 (t, J = 6.9 Hz, 1H, CH), 5.62 (d, J = 8.1 Hz, 1H, Ar-H), 5.51 (s, 1H, OH),
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4.67 (dd, J = 14.2, 4.5 Hz, 1H, CH2), 4.57 (dd, J = 14.3, 7.7 Hz, 1H, CH2), 4.67–4.44 (d, J = 5.7 Hz, 2H,
CH2), 4.28–4.19 (m, 1H, CH), 4.12–4.02 (m, 1H, CH), 2.25–2.04 (m, 2H, CH2); 13C-NMR (101 MHz,
DMSO-d6): δ 167.81, 163.02, 153.79, 151.53, 150.41, 146.52, 145.18, 140.74, 123.64, 119.43, 119.20, 117.68,
117.62, 113.96, 113.71, 113.48, 102.10, 84.44, 84.27, 70.79, 51.23, 38.10, 34.55; HRMS (ESI) m/z calcd.
for C19H20FN7O5 [M + Na]+ 468.1402, found 468.1401.
2-Amino-5-bromo-N-((1-(((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran
-2-yl) methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (9e): Following the general procedure B,
the title product was obtained as off-white solid (53 mg, 52%); 1H-NMR (400 MHz, DMSO-d6):
δ 11.32 (bs, 1H, NH), 8.87 (t, J = 5.7, 1H, NH), 7.95 (s, 1H, Ar-H), 7.67 (d, J = 2.4 Hz, 1H, Ar-H),
7.56 (d, J = 8.1 Hz, 1H, Ar-H), 7.26 (dd, J = 8.8, 2.3 Hz, 1H, Ar-H), 6.67 (d, J = 8.9 Hz, 1H, Ar-H),
6.58 (s, 2H, NH2), 6.14 (t, J = 6.9 Hz, 1H, CH), 5.62 (d, J = 8.0 Hz, 1H, Ar-H), 5.50 (d, J = 4.3 Hz,
1H, OH), 4.61 (d, J = 4.5 Hz, 1H, CH2), 4.49 (d, J = 7.6 Hz, 1H, CH2), 4.43 (d, J = 5.6 Hz, 2H, CH2),
4.26–4.21 (m, 1H, CH), 4.14–4.02 (m, 1H, CH), 2.23–2.04 (m, 2H, CH2); 13C-NMR (101 MHz, DMSO-d6):
δ 168.00, 163.45, 150.85, 149.44, 145.57, 141.18, 134.74, 134.71, 130.71, 124.05, 118.94, 116.10, 105.38,
102.55, 84.87, 84.72, 71.24, 38.54, 34.96; HRMS (ESI) m/z calcd. for C19H20BrN7O5 [M + Na]+ 528.0602,
found 528.0600.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (12a): Following the general procedure B, the title
product was obtained as off-white solid (65 mg, 61%); 1H-NMR (400 MHz, DMSO-d6): δ 11.24 (bs, 1H,
NH), 8.73 (t, 1H, NH), 8.12 (d, J = 7.5 Hz, 1H, Ar-H), 8.05–7.98 (m, 3H, Ar-H), 7.62 (t, J = 7.4 Hz, 1H,
Ar-H), 7.56–7.46 (m, 3H, Ar-H), 7.37 (s, 1H, Ar-H), 7.13–7.07 (m, 1H, Ar-H), 6.67 (dd, J = 8.2, 1.2 Hz, 1H,
Ar-H), 6.48 (t, J = 1.0 Hz, 1H, Ar-H), 6.41 (s, 2H, NH2), 6.16 (t, J = 6.5 Hz, 1H, CH), 5.54 (d, J = 4.2 Hz,
1H, OH), 4.76–4.61 (m, 2H, CH2), 4.46 (d, J = 5.7 Hz, 2H, CH2), 4.30–4.22 (m, 1H, CH), 4.22–4.14 (m, 1H,
CH), 2.37–2.09 (m, 2H, CH2); 13C-NMR (151 MHz, DMSO-d6): δ 168.82, 149.76, 145.52, 132.76, 131.77,
128.46, 128.13, 123.66, 116.35, 114.52, 114.19, 87.18, 84.94, 70.77, 51.22, 34.47; HRMS (ESI) m/z calcd.
for C26H26N8O5 [M + H]+ 531.2099, found 531.2098.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl) methyl)-5-methoxybenzamide (12b): Following the general procedure B,
the title product was obtained as light brown solid (70 mg, 62%); 1H-NMR (400 MHz, DMSO-d6):
δ 11.25 (bs, 1H, NH), 8.79 (t, J = 5.7 Hz, 1H, NH), 8.13 (d, J = 7.6 Hz, 1H, Ar-H), 8.06–7.96 (m, 3H, Ar-H),
7.68–7.59 (m, 1H, Ar-H), 7.53 (t, J = 8.3, 7.0 Hz, 2H, Ar-H), 7.38 (s, 1H, Ar-H), 7.09 (d, J = 2.9 Hz, 1H,
Ar-H), 6.82 (dd, J = 8.9, 2.8 Hz, 1H, Ar-H), 6.65 (d, J = 8.9 Hz, 1H, Ar-H), 6.16 (t, J = 6.5 Hz, 1H, CH),
6.00 (s, 2H, NH2), 5.56 (d, J = 4.3 Hz, 1H, OH), 4.78–4.62 (m, 2H, CH2), 4.47 (d, J = 5.7 Hz, 2H, CH2),
4.34–4.23 (m, 1H, CH), 4.24–4.12 (m, 1H, CH), 3.66 (s, 3H, CH3) 2.38–2.09 (m, 2H, CH2); 13C-NMR
(151 MHz, DMSO-d6): δ 168.56, 149.31, 145.46, 144.04, 132.78, 128.50, 128.47, 123.71, 119.89, 117.81,
114.32, 111.81, 86.53, 84.95, 70.79, 55.56, 51.26, 34.49; HRMS (ESI) m/z calcd. for C27H29N8O6 [M + H]+
561.2205, found 561.2204.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-fluorobenzamide (12c): Following the general procedure B,
the title product was obtained as light yellowish solid (80 mg, 73%); 1H-NMR (400 MHz, DMSO-d6):
δ 11.24 (bs, 1H, NH), 8.81 (t, J = 5.7 Hz, 1H, NH), 8.12 (d, J = 7.5 Hz, 1H, Ar-H), 8.05–7.98 (m, 3H, Ar-H),
7.67–7.59 (m, 1H, Ar-H), 7.52 (t, J = 7.7 Hz, 2H, Ar-H), 7.36 (dd, J = 10.3, 3.0 Hz, 2H, Ar-H), 7.06–6.92
(m, 1H, Ar-H), 6.69 (dd, J = 9.0, 5.0 Hz, 1H, Ar-H), 6.31 (s, 2H, NH2), 6.16 (t, J = 6.5 Hz, 1H, CH),
5.54 (d, J = 4.3 Hz, 1H, OH), 4.69 (dd, J = 8.9, 6.1 Hz, 2H, CH2), 4.46 (d, J = 5.6 Hz, 2H, CH2), 4.30–4.23
(m, 1H, CH), 4.26–4.15 (m, 1H, CH), 2.38–2.10 (m, 1H, CH2); 13C-NMR (101 MHz, DMSO-d6): δ 167.85,
153.71, 151.86, 148.73, 146.50, 145.22, 132.74, 128.43, 123.68, 119.48, 119.14, 117.61, 113.67, 113.45, 86.76,
84.92, 70.77, 50.80, 34.52; HRMS (ESI) m/z calcd. for C25H26FN8O5 [M + Na]+ 571.1824, found 571.1823.
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2-Amino-N-((1-(((2R,3S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-chlorobenzamide (12d): Following the general procedure
B, the title product was obtained as off-white solid (70 mg, 62%); 1H-NMR (400 MHz, DMSO-d6):
δ 11.22 (bs, 1H, NH), 8.90 (t, 1H, NH), 8.12 (d, J = 7.3 Hz, 1H, Ar-H), 8.06–7.94 (m, 4H, Ar-H),
7.62 (t, 1H, Ar-H), 7.57 (d, J = 2.5 Hz, 1H, Ar-H), 7.52 (t, J = 7.7 Hz, 2H, Ar-H), 7.13 (dd, J = 8.8, 2.5 Hz,
1H, Ar-H), 6.71 (d, J = 8.8 Hz, 1H, Ar-H), 6.56 (s, 2H, NH2,), 6.15 (t, 1H, CH), 5.63 (d, J = 4.3 Hz, 1H,
OH), 4.78–4.62 (m, 2H, CH2), 4.45 (d, J = 5.6 Hz, 2H, CH2), 4.30–4.22 (m, 1H, CH), 4.26–4.15 (m, 1H,
CH), 2.41–2.10 (m, 1H, CH2); 13C-NMR (151 MHz, DMSO-d6): δ 167.63, 148.69, 145.20, 132.78, 131.53,
128.50, 128.47, 127.47, 123.72, 118.06, 117.72, 114.97, 96.44, 84.93, 70.73, 51.26, 34.52; HRMS (ESI) m/z
calcd. for C26H26ClN8O5 [M + H]+ 565.1709, found 565.1709.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-bromobenzamide (12e): Following the general procedure B,
the title product was obtained as off-white solid (65 mg, 53%); 1H-NMR (600 MHz, DMSO-d6): δ 11.26
(bs, 1H, NH), 8.89 (t, J = 5.9 Hz, 1H, NH), 8.12 (d, J = 7.6 Hz, 1H, Ar-H), 8.06–7.98 (m, 3H, Ar-H),
7.68 (d, J = 2.4 Hz, 1H, Ar-H), 7.63 (t, J = 7.3 Hz, 1H, Ar-H), 7.52 (t, J = 7.7 Hz, 2H, Ar-H), 7.40–7.34
(m, 1H, Ar-H) 7.24 (dd, J = 8.8, 2.4 Hz, 1H, Ar-H), 6.67 (d, J = 8.8 Hz, 1H, Ar-H), 6.59 (s, 2H, NH2),
6.17 (t, J = 6.5 Hz, 1H, CH), 5.56 (d, J = 4.3 Hz, 1H, OH), 4.81–4.64 (m, 2H CH2), 4.45 (d, J = 5.8 Hz, 2H,
CH2), 4.29–4.24 (m, 1H, CH), 4.24–4.17 (m, 1H, CH), 2.32–2.02 (m, 2H, CH2); 13C-NMR (151 MHz,
DMSO-d6): δ 167.98, 149.46, 145.65, 134.69, 130.72, 128.95, 128.90, 124.14, 118.92, 116.06, 105.36, 85.39,
79.66, 79.44, 79.22, 71.24, 51.72, 34.97; HRMS (ESI) m/z calcd. for C26H25BrN8O5 [M + Na]+ 631.1023,
found 631.1022.
General procedure (C) for the deprotection of benzoyl group: To a solution of N-benzoyl triazole
(0.1 mmol) in methanol (6 mL), Aq. NH3 (28%) (6 mL) was added. The resulting mixture was stirred at
rt for 16 h. After completion of the reaction, solvent was evaporated in vacuo, crude was purified by
dissolving in methanol (1 mL), then, excess diethyl ether was added, and solid precipitate was collected
and dried, which gives desired compound as off-white to light brown solid between (81–92% yields).
2-Amino-N-((1-(((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide (13a): Following the general procedure C, the title
product was obtained as off-white solid (38 mg, 88%); 1H-NMR (600 MHz, DMSO-d6): δ 8.73 (t, J = 5.8,
1H, NH), 7.94 (s, 1H, Ar-H), 7.52 (d, J = 7.5 Hz, 1H, Ar-H), 7.50 (dd, J = 8.0, 1.5 Hz, 1H, Ar-H),
7.14 (s, 2H, NH2), 7.13 (td, J = 8.4, 7.0, 1.5 Hz, 1H, Ar-H), 6.69 (dd, J = 8.2, 1.2 Hz, 1H, Ar-H),
6.50 (td, J = 8.1, 7.0, 1.2 Hz, 1H, Ar-H), 6.42 (s, 2H, NH2), 6.18 (t, J = 7.5, 6.2 Hz, 1H, CH), 5.75 (d, J = 7.4,
1H, Ar-H), 5.45 (d, J = 4.3 Hz, 1H, OH), 4.66 (dd, J = 14.3, 4.4 Hz, 1H, CH2), 4.58 (dd, J = 14.2, 7.7 Hz,
1H, CH2), 4.45 (d, J = 5.7 Hz, 2H, CH2), 4.22–4.21 (m, 3.6 Hz, 1H, CH), 4.09–4.06 (m, 4.2 Hz, 1H, CH),
2.14–2.08 (m, 1H, CH2), 2.05–1.98 (m, 1H, CH2); 13C-NMR (101 MHz, DMSO-d6): δ 168.84, 165.55,
154.99, 149.76, 145.42, 141.12, 131.83, 128.17, 123.60, 116.39, 114.60, 114.25, 94.41, 85.17, 84.17, 70.98,
51.38, 39.55, 34.48. HRMS (ESI) m/z calcd. for C19H22N8O4 [M + H]+ 449.1656, found 449.1655.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methoxybenzamide (13b): Following the general procedure C,
the title product was obtained as light brown solid (37 mg, 81%); 1H-NMR (400 MHz, DMSO-d6):
δ 8.77 (t, J = 5.7 Hz, 1H, NH), 7.95 (s, 1H, Ar-H), 7.53 (d, J = 7.4 Hz, 1H, Ar-H), 7.28–7.12 (m, 2H,
NH2), 7.09 (d, J = 2.9 Hz, 1H, Ar-H), 6.84 (dd, J = 8.9, 2.9 Hz, 1H, Ar-H), 6.66 (d, J = 8.9 Hz, 1H),
6.18 (t, J = 6.8 Hz, 1H, CH), 6.01 (s, 2H, NH2), 5.75 (d, J = 7.4 Hz, 1H, Ar-H), 5.47 (d, J = 4.2 Hz, 1H,
OH), 4.62 (dd, J = 21.4, 6.1 Hz, 2H, CH2), 4.46 (d, J = 5.6 Hz, 2H, CH2), 4.23–4.22 (m, 1H, CH), 4.12–4.04
(m, 1H, CH), 3.67 (s, 3H, OCH3), 2.23–1.96 (m, 2H, CH2); 13C-NMR (101 MHz, DMSO-d6): δ 169.00,
165.99, 155.42, 149.78, 145.78, 144.47, 141.57, 124.08, 120.35, 118.27, 114.83, 112.30, 94.83, 85.62, 84.61,
71.43, 56.04, 51.84, 34.94; HRMS (ESI) m/z calcd. for C20H24N8O5 [M + Na]+ 479.1762, found 479.1760.
Molecules 2020, 25, 3103 14 of 17
2-Amino-N-((1-(((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-fluorobenzamide (13c): Following the general procedure C,
the title product was obtained as off-white solid (41 mg, 92%); 1H-NMR (400 MHz, DMSO-d6): δ 8.82
(t, J = 5.6 Hz, 1H, NH), 7.97 (s, 1H, Ar-H), 7.52 (d, J = 7.5 Hz, 1H, Ar-H), 7.37 (dd, J = 10.3, 3.0 Hz, 1H,
Ar-H), 7.17 (d, J = 13.1 Hz, 2H, NH2), 7.09–7.00 (m, 1H, Ar-H), 6.70 (dd, J = 9.0, 5.0 Hz, 1H, Ar-H),
6.33 (s, 2H, NH2), 6.17 (t, 1H, J = 6.8 Hz, CH), 5.73 (d, J = 7.4 Hz, 1H, Ar-H), 5.45 (d, J = 4.3 Hz, 1H,
OH), 4.75–4.53 (m, 2H, CH2), 4.44 (d, J = 5.7 Hz, 2H, CH2) 4.24–4.16 (m, 1H, CH), 4.11–4.03 (m, 1H,
CH), 2.16–1.95 (m, 2H, CH2); 13C-NMR (101 MHz, DMSO-d6): δ 167.78, 165.54, 154.98, 153.80, 151.48,
146.51, 145.13, 141.13, 123.62, 119.42, 119.19, 117.66, 117.58, 113.96, 113.90, 113.72, 113.50, 94.39, 85.19,
84.15, 70.98, 51.40, 34.52; HRMS (ESI) m/z calcd. for C19H22FN8O4 [M + Na]+ 567.1562, found 567.1564.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-chlorobenzamide (13d): Following the general procedure C,
the title product was obtained as off-white solid (38 mg, 82%); 1H-NMR (600 MHz, DMSO-d6): δ 8.88
(t, J = 5.7 Hz, 1H, NH), 7.96 (s, 1H, Ar-H), 7.57 (d, J = 2.5 Hz, 1H, Ar-H), 7.52 (d, J = 7.4 Hz, 1H, Ar-H),
7.26–6.99 (m, 3H, NH2, Ar-H), 6.72 (d, J = 8.8 Hz, 1H, Ar-H), 6.57 (s, 2H, NH2), 6.17 (t, J = 7.5, 6.2 Hz,
1H, CH), 5.74 (d, J = 7.4 Hz, 1H, Ar-H), 5.46 (d, J = 4.0 Hz, 1H, OH), 4.66 (dd, J = 14.2, 4.4 Hz, 1H, CH2),
4.57 (dd, J = 14.2, 7.7 Hz, 1H, CH2), 4.44 (d, J = 5.6 Hz, 2H, CH2), 4.25–4.19 (m, 1H, CH), 4.08–4.05
(m, 1H, CH), 2.12–2.07 (m, 1H, CH2), 2.03–1.99 (m, 1H, CH2); 13C-NMR (151 MHz, DMSO-d6): δ 168.06,
165.98, 155.41, 149.12, 145.53, 141.57, 132.02, 127.92, 124.06, 118.51, 118.19, 115.45, 108.11, 94.83, 85.61,
84.60, 71.42, 51.85, 34.96; HRMS (ESI) m/z calcd. for C19H21ClN8O4 [M + H]+ 483.1267, found 483.1264.
2-Amino-N-((1-(((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)
methyl)-1H-1,2,3-triazol-4-yl)methyl)-5-bromobenzamide (13e): Following the general procedure C,
the title product was obtained as off-white solid (43 mg, 85%); 1H-NMR (400 MHz, DMSO-d6): δ 8.87
(t, J = 5.5 Hz, 1H, NH), 7.96 (s, 1H, Ar-H), 7.68 (d, J = 2.4 Hz, 1H, Ar-H), 7.52 (d, J = 7.4 Hz, 1H,
Ar-H), 7.26 (dd, J = 8.9, 2.3 Hz, 1H, Ar-H), 7.17 (s, 2H, NH2), 6.67 (d, J = 8.8 Hz, 1H, Ar-H), 6.58 (s, 2H,
NH2), 6.17 (t, J = 6.8 Hz, 1H, CH), 5.76 (s, 1H, Ar-H), 5.45 (d, J = 4.3 Hz, 1H, OH), 4.65– 4.58 (m, 2H,
CH2), 4.43 (d, J = 5.5 Hz, 2H, CH2), 4.24–4.16 (m, 1H, CH), 4.11–4.03 (m, 1H, CH), 2.10–1.95 (m, 2H,
CH2); 13C-NMR (151 MHz, DMSO-d6): δ 167.52, 165.54, 148.99, 145.07, 141.12, 134.26, 130.27, 123.61,
118.47, 115.62, 104.92, 85.18, 84.15, 70.97, 69.79, 51.39, 34.50; HRMS (ESI) m/z calcd. for C19H21BrN8O4
[M + H]+ 505.0942, found 505.0942.
4.2. Biological Activity
For the pqs:gfp reporter assay, the PAO1 pqsA-gfp P. aeruginosa strain carries the PqsR-regulated pqsA
promoter fused to gfp [35]. The compounds were dissolved in DMSO at a concentration of 20 mg/mL
(approximately 40 mM based on molecular weights). The assays with pqsA reporters were carried
out in MHB (Mueller Hinton Broth) in 96-well plates, at 37 ◦C with intermittent shaking. Readings
were taken every 15 min for both OD600 and fluorescence; the fluorescence values shown in the graph
were normalized with respect to OD600. All the reporters tested peak in promoter activity after 6–8 h
growth. At intervals of 15 min, both GFP fluorescence and OD600 were recorded. Negative control
refers to medium containing the same concentration of DMSO as the highest concentration of the
test compound.
For microscopy imaging to evaluate adhesion and biofilm formation, planktonic cultures of
PAO1 were grown for 24 h followed by re-suspension in TSB media when a bacterial density of
OD600 = 0.10 ± 0.02 was reached. Then, 600 µL of the re-suspended cells was added to 12-well plates
(Corning Corp. USA), and then, incubated at 37 ◦C and 100 rpm to initiate bacterial adhesion and
biofilm growth. Samples contained either compounds at 400 µM, or TSB medium or DMSO as negative
controls. After 24 h, wells were washed twice with 1×PBS to remove any loosely adhered bacteria and
imaged using phase contrast microscopy (Zeiss, Axio, Germany), for bacterial adhesion, aggregation
and biofilm formation as described [36].
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For pyocyanin quantification, planktonic cultures of PAO1 were grown in 12-wells plate for 24 h in
presence of plain TSB, solvent (DMSO) and compounds 400 µM. After growth, the planktonic cultures
were transferred into sterile 2 mL Eppendorf tubes and centrifuged at 5000 g for 10 min at 21◦C.
After centrifugation, the supernatant was removed by pipetting and transferred into new Eppendorf
tubes, followed by re-centrifuging at 5000× g for 10 min at 21 ◦C. The supernatants were filtered using
0.4 µM filters and added to 96-well plates, and pyocyanin concentration was determined by measuring
absorbance at OD695 using a plate reader (Tecan infinite M1000 pro, Sydney, Australia).
5. Conclusions
Inhibition of the PQS quorum sensing system is an attractive target for the development
of alternative therapies against multidrug-resistant P. aeruginosa. Anthraniloyl-AMP mimics are
competitive antagonists of the enzyme PqsA, and block production of virulence factors PQS and
HHQ without affecting bacterial growth. In this study, we have designed and synthesized 14 novel
anthraniloyl-AMP mimics containing a triazole linker as potential inhibitors of Pseudomonas quinolone
biosynthesis. However, most of these analogues did not show PQS inhibitory activity against a
P. aeruginosa reporter chain except for deoxycytidine analogue (13e), which inhibited PQS activity
by 30% at 125 µM, possibly due to limited cell penetration. Interestingly, these compounds induced
significant morphological changes in biofilms as observed by microscopy, suggesting that they could
inhibit PQS or other signaling systems responsible for bacterial aggregation. Our future efforts will
focus on modifying these analogues to increase bacterial cell penetration.
Supplementary Materials: The 1H- and 13C-NMR spectra for all the new compounds and growth inhibition data
are provided in the supplementary file.
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